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Abstract
Background: Clinical decision-making of invasive high-intensity care for critically ill stage IV cancer patients in the
emergency department (ED) is challenging. A reliable and clinically available prognostic score for advanced cancer
patients with septic shock presented at ED is essential to improve the quality of intensive care unit care. This study
aimed to develop a new prognostic score for advanced solid cancer patients with septic shock available early in
the ED and to compare the performance to the previous severity scores.
Methods: This multi-center, prospective cohort study included consecutive adult septic shock patients with stage
IV solid cancer. A new scoring system for 28-day mortality was developed and validated using the data of
development (January 2016 to December 2017; n = 469) and validation sets (January 2018 to June 2019; n = 428).
The developed score’s performance was compared to that of the previous severity scores.
Results: New scoring system for 28-day mortality was based on six variables (score range, 0–8): vital signs at ED
presentation (respiratory rate, body temperature, and altered mentation), lung cancer type, and two laboratory
values (lactate and albumin) in septic shock (VitaL CLASS). The C-statistic of the VitaL CLASS score was 0.808 in the
development set and 0.736 in the validation set, that is superior to that of the Sequential Organ Failure Assessment
score (0.656, p = 0.01) and similar to that of the Acute Physiology and Chronic Health Evaluation II score (0.682, p =
0.08). This score could identify 41% of patients with a low-risk group (observed 28-day mortality, 10.3%) and 7% of
patients with a high-risk group (observed 28-day mortality, 73.3%).
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Conclusions: The VitaL CLASS score could be used for both risk stratification and as part of a shared clinical
decision-making strategy for stage IV solid cancer patients with septic shock admitting at ED within several hours.
Keywords: Septic shock, Sepsis, Neoplasms, Prognosis, Critical care
Background
Cancer is a major public health burden; both cancer in-
cidence and mortality are expected to increase rapidly
worldwide. Recent advances in cancer treatment have
improved the overall survival rates; however, they have
also increased the possibility of developing a critical
illness requiring intensive care unit (ICU) manage-
ment [1, 2]. Approximately 5% of the patients with
solid cancer require ICU admission within 2 years
after diagnosis [1, 2].
Sepsis and septic shock associated with cancer
progression or chemo-radiation-therapy is a common
life-threatening complication in cancer patients. Recent
studies have demonstrated improved outcomes in cancer
patients admitted to the ICU, and with appropriate pa-
tient selection, the outcomes of patients with or without
cancer could be similar [3–5]. However, the decision of
invasive ICU treatments for advanced cancer patients
with septic shock is still challenging, especially in the
emergency department (ED) setting. The clinical
decision-making for advanced cancer patients with
septic shock in the ED comprises more than 3 of health
care specialties: critical care medicine, emergency medi-
cine, oncology, and surgery. Treatment recommenda-
tions for these patients could be different depending on
the specialties [6, 7]. Also, the patient-physician commu-
nication in such situations frequently leads to overutili-
zation of invasive ICU treatments, which can produce
more costly and invasive care without improving out-
comes [8–10].
Sequential Organ Failure Assessment (SOFA) and
Acute Physiology and Chronic Health Evaluation
(APACHE) II scores are valid and widely used clinical
prediction tools to determine the mortality risk, but
they are designed to be calculated on the worst pa-
rameters recorded during the initial 24 h after admis-
sion and are not reliable at ED presentation [11, 12].
A reliable and clinically available prognostic score for
advanced cancer patients with septic shock presented
at ED is essential to improve the quality and effi-
ciency of ICU care. To address this issue, we aimed
to develop a new prognostic model for stage IV can-
cer patients who present with septic shock available
at ED and compare its performance to existing scor-
ing systems including SOFA score, APACHE II score,
quick SOFA score, National Early Warning Score, and
Modified Early Warning Score.
Methods
Study design and population
This multi-center, prospective observational study was
conducted in the EDs of 11 Korean university-affiliated,
tertiary referral centers using data from the Korean
Shock Society septic shock registry, from January 2016
to December 2018. The Korean Shock Society is a
Korean collaborative research network, established in
2013, for improving the quality of research, diagnosis,
and management of sepsis [13]. Since October 2015, 11
EDs in the Korean Shock Society have been prospect-
ively collecting data pertaining to patients with septic
shock [13]. Adult patients (aged ≥ 19 years) who visited
one of these EDs with suspected or confirmed infection
and evidence of refractory hypotension or hypoperfusion
were enrolled in the registry [14–16]. Refractory
hypotension was defined as persistent systolic blood
pressure < 90mmHg, mean arterial pressure < 70mmHg,
or systolic blood pressure decrease > 40 mmHg after ≥
20–30mL/kg intravenous fluid administration or requir-
ing vasopressors to maintain systolic blood pressure of
≥ 90mmHg or mean arterial pressure of ≥ 70 mmHg
[17]. Hypoperfusion was defined as serum lactate level
of ≥ 4 mmol/L [18]. Exclusion criteria included patients
who refused ICU management, patients who signed a
“do not attempt resuscitation” order before ED arrival or
at the time of diagnosis, patients who met the inclusion
criteria 6 h after ED arrival, patients who were trans-
ferred from other hospitals after stabilization, patients
who were directly transferred to other hospitals at ED,
or patients who refused to enroll in the registry [13].
The institutional review boards of each participating in-
stitute approved the registry, and informed consent was
obtained before data collection.
This study included patients with stage IV solid cancer
who were enrolled in the septic shock registry and
treated with intensive care between 1 January 2016 and
30 June 2019. The final cohort for this study included
897 patients; those selected from 1 January 2016 to 31
December 2017 were included in the development set
(n = 469, 52.3%) and those selected from 1 January 2018
to 30 June 2019, in the validation set (n = 428, 47.7%).
Management and data collection
All patients were treated in accordance with then-
current guidelines of the Surviving Sepsis Campaign in-
cluding crystalloid administration, acquisition of blood
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cultures before antibiotic administration, and broad-
spectrum antibiotic administration and vasopressor ad-
ministration [17, 19]. The decision for subsequent inten-
sive care was based on the intensivist according to
institutional protocols. Empirical broad-spectrum antibi-
otics, such as piperacillin/tazobactam, cefepime, and
meropenem, were administrated immediately after blood
cultures at the ED, and after admission, further anti-
biotic treatments were adjusted.
The case report form of the Korean Shock Society sep-
tic shock registry includes standard definitions of 200
variables including demographic and clinical characteris-
tics, therapeutic interventions, and outcomes. Data of
the Korean Shock Society septic shock registry are col-
lected via a standardized case report form and entered
into a web-based electronic database [13]. The quality
management committee monitors and reviews the com-
pleteness and consistency of data regularly and also gives
feedback to the research coordinators and investigators
of the results of the quality management process by
using the web system’s query function or via a telephone
call.
Data regarding age, sex, comorbid disease, focus of in-
fection, laboratory findings, vital signs at ED presenta-
tion, and SOFA and APACHE II scores were retrieved
from the registry. Mental status at ED presentation was
assessed using the Alert/responsive to Voice/responsive
to Pain/Unresponsive scale; unalert patients were con-
sidered to have altered mentation. Cancer type was
reviewed additionally for this study using the diagnosis
codes according to the International Statistical Classifi-
cation of Diseases and Related Health Problems, Tenth
Revision. We categorized the cases according to six
common solid cancer types as follows: gastrointestinal
cancer (C15-C20), hepatobiliary-pancreas cancer (C22-
C25), lung cancer (C33-C34), gynecologic cancer (C53-
C56), urologic cancer (C61-67), and “others/ill-defined”
cancer. All blood samples for laboratory analysis includ-
ing lactic acid were obtained from the patients at their
initial presentation. SOFA and APACHE II scores were
calculated using the worst parameters during the initial
24 h after ED admission. The quick SOFA score, Na-
tional Early Warning Score, and Modified Early Warning
Score were calculated using the initial vital signs at ED
admission [20–22]. The primary endpoint of this study
was 28-day mortality.
Statistical analysis
Categorical variables were presented as frequencies and
percentages, and continuous variables as median with
interquartile range (IQR). The χ2 test was used to com-
pare categorical variables of development and validation
sets, and the continuous variables for survivors and non-
survivors of development and validation sets were
compared using the t test or the Wilcoxon rank-sum
test if the distribution was not normal. Lactic acid level
was categorized into 3 groups (twice above the normal
limit [≥ 4 mmol/L], 4 to 8 mmol/L, fourfold or more
above the normal limit [≥ 8 mmol/L]) based on the pre-
vious guidelines and study [17, 23].
In the development set, univariate Cox proportional
hazard analysis was performed to evaluate the prognostic
ability of each variable. The variables in the scoring sys-
tem were selected among all variables by using multivar-
iable Cox proportional hazard analysis with backward
elimination in 1000-fold bootstrap resampling [24].
Then, we counted how many times each candidate vari-
able remained in the model in the 1000 bootstrap sam-
ples. If a variable appeared > 500 times in the final
model, the variable was included in the scoring system.
To allocate points in the scoring system, the bootstrap-
ping method was used again to obtain bias-corrected re-
gression coefficients to assign risk points in the scoring
system. Risk points were obtained by bias-corrected re-
gression coefficients multiplied by a reference value in
the corresponding category. Each risk point was rescaled
to designate the point of lung cancer as 1 (for example,
the risk point for respiratory rate ≥ 22/min was 1, which
was rounded from 0.891/0.617 = 1.444). A reference risk
factor profile was chosen by selecting a base category for
each risk factor, which was assigned 0 points in the scor-
ing system. The total score was the weighted sum of
those predictors of which the weights were defined as
the rounded integer value of the quotient of regression
coefficients divided by the regression coefficient of the
reference predictor. The total scores based on patient
profiles were converted into a risk estimate by using a
specific formulation as below [25].





The calibration and discrimination of the final multi-
variable Cox proportional hazards model were assessed
by calibration curve [26] and the Harrell C-statistic [27],
respectively. The calibration measure compared the pre-
dicted and observed probability after data were parti-
tioned into several groups. The discrimination index
measured the concordance probability that predicted
probabilities from a randomly selected pair of survivors
and non-survivors. We categorized the groups based on
the likelihood of 28-day mortality: low (score of 0–2,
7.07%), average (score of 3–5, 36.03%), and high (score
of 6–8, 89.47%). Finally, we compared the C-index and
Akaike information criterion of our new prognostic
score with those of the SOFA and APACHE II scores
using R package “compareC” [28].
All reported p values were 2-sided, and p < 0.05 was
considered significant. All statistical analyses were
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performed using the SAS version 9.4 (SAS Institute Inc.,
Cary, NC, USA) and R (version 3.6.1; R Foundation for
Statistical Computing, Vienna, Austria; https://www.R-
project.org).
Results
During the study period, a total of 3486 patients with
septic shock were enrolled in the Korean Shock Society
septic shock registry, of which 897 (25.7%) patients with
stage IV solid cancer were included. The overall 28-day
mortality rate was 26.4% (237/897) and 499 (55.6%) pa-
tients admitted to ICU. The general characteristics of
our study patients including those in the development
(n = 469, 52.3%) and validation (n = 428, 47.7%) cohorts
are presented in Table 1. The median age of our cohort
was 66 years, and hepatobiliary-pancreas cancer (31.9%)
and lung cancer (16.8%) were the dominant cancer
types. Patients in the validation set showed significantly
higher initial lactate level (median, 3.4 vs. 3.7 mmol/L,
p = 0.03), SOFA (median, 7.0 vs. 8.0, p = 0.002), and
APACHE II (median, 19.0 vs. 21.0, p = 0.04) scores.
The univariable Cox proportional hazards model for
predicting the 28-day mortality in the development set is
summarized in Table 2. The bootstrap resampling vari-
able selection method provided six variables: respiratory
rate, body temperature, altered mentation at ED presen-
tation, lung cancer, lactic acid, and albumin. We per-
formed a second multivariate Cox proportional hazards
analysis using only those six final independent variables,
and the final prediction model was developed based on
the bias-corrected regression coefficients as shown in
Tables 3 and 4. We named this new prognostic scoring
system the VitaL CLASS score (vital signs-lung cancer-
lactate-albumin in septic shock). The C-statistic for the
VitaL CLASS score was 0.808 (95% confidence interval
[CI], 0.772–0.845) in the development set and 0.736
(95% CI, 0.694–0.778) in the validation set (Table 5). In
the development set, the C-static for the VitaL CLASS
score was superior to that of the existing scoring systems
such as the SOFA (0.713; 95% CI, 0.664–0.762; p =
0.001) and APACHE II (0.692; 95% CI, 0.643–0.741; p <
0.001). In the validation set, the C-statistic of the VitaL
CLASS score (0.736) was superior to that of the SOFA
score (0.656; p = 0.01) and similar to that of the APAC
HE II score (0.682; p = 0.08). The calibration curve of
our new score demonstrated good correlation between
the predicted and actual probability of 28-day mortality
in both sets (Fig. 1). A subgroup analysis of the patients
who fulfill the sepsis-3 criteria for septic shock was per-
formed. Additional file 1: Table S1 shows there was no
difference in general characteristics between develop-
ment and validation subgroup cohorts. The VitaL CLAS
S score of the patients who fulfill the sepsis-3 criteria for
septic shock demonstrated superior prognostic
performance to the existing scoring systems in the devel-
opment set (C-index, 0.806; 95% CI, 0.761–0.851), and
similar performance to SOFA and APACHE II scores
in the validation set (C-index, 0.702; 95% CI, 0.649–
0.755) (Additional file 2: Table S2).
Table 6 shows the performance of the final point score
and risk groups according to the VitaL CLASS score in
development and validation datasets. Based on the esti-
mate of probability for 28-day mortality, the VitaL CLAS
S score classified the patients into 3 groups: low (0–2),
average (3–5), and high (6–8) risk groups. In the valid-
ation set, the VitaL CLASS score identified 40.9% and
7.0% of the patients as having a low risk and high risk of
28-day mortality, respectively. The patients in the low-
risk group had 10.3% (18/175) of mortality, whereas
73.3% (22/30) of the patients in the high-risk group died
within 28 days after admission.
Discussion
We developed and validated a simple and objective
prognostic model, the VitaL CLASS score, which is ap-
plicable in the ED very early. This scoring system could
identify stage IV cancer patients who present to the ED
with septic shock as having low, average, or high risk of
death within 28 days. Using this score, it would be help-
ful to triage patients in the high-risk group, who have a
low possibility of benefitting from intensive care, and
those in the low-risk group, who have a high likelihood
of survival. This risk assessment would help physicians
share information with patients and family and establish
goals-of-care among physicians of different specialties as
well as patients in the ED regarding life-sustaining
treatments including mechanical ventilation, vaso-
active infusions, new renal replacement therapy, or
cardiopulmonary resuscitation and physician orders
for life-sustaining treatment (POLST) orders. The
VitaL CLASS score shows good prognostic perform-
ance and is simple and fast to use, comparing to exist-
ing scoring systems, SOFA and APACHE II scores.
The VitaL CLASS score to predict short-term mortal-
ity among stage IV cancer patients with septic shock
consists of four clinical factors identified at ED presenta-
tion: cancer type (lung cancer and the other types of
cancer), respiratory rate, body temperature and altered
mentation, and two laboratory values reported within
hours, i.e., lactic acid and albumin. This simple and ob-
jective prognostic model for stage IV cancer patients
with septic shock uses data available within hours after
ED admission. The majority of patients with advanced
medical illness would prefer palliative approaches to in-
vasive ICU treatments when they were informed of their
therapeutic options, and such invasive ICU treatments
should be aligned with patients’ values and prognostic
information [10, 29–31]. Furthermore, the demand for
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Table 1 Characteristics of the patients in the development set and validation set
Characteristics Total set (N = 897) Development set (n = 469) Validation set (n = 428) p value
Age, years 66.0 (59.0–74.0) 67.0 (60.0–74.0) 66.0 (59.0–75.0) 0.38
Male 561 (62.5) 292 (62.3) 269 (62.9) 0.86
Hypertension 281 (31.3) 143 (30.5) 138 (32.2) 0.57
Diabetes mellitus 207 (23.1) 122 (26.0) 85 (19.9) 0.09
Cancer type 0.46
Gastrointestinal 137 (15.3) 62 (13.2) 75 (17.5)
Hepatobiliary-pancreas 286 (31.9) 151 (32.2) 135 (31.5)
Lung 151 (16.8) 79 (16.8) 72 (16.8)
Gynecologic 82 (9.1) 49 (10.5) 33 (7.7)
Urologic 78 (8.7) 42 (9.0) 36 (8.4)
Others 163 (18.2) 86 (18.3) 77 (18.0)
Focus of infection 0.21
Pneumonia 209 (23.3) 106 (22.6) 103 (24.1)
Urinary tract infection 116 (12.9) 65 (13.9) 51 (11.9)
Colitis 129 (14.4) 59 (12.6) 70 (16.4)
Cholangitis/cholecystitis 238 (26.5) 130 (27.7) 108 (25.2)
Others/unknown 129 (14.4) 75 (16.0) 54 (12.6)
Multiple focus 76 (8.5) 34 (7.3) 42 (9.8)
Vital signs at ED admission
Systolic BP, mmHg 90.0 (77.0–111.0) 90.0 (79.0–112.0) 89.0 (76.0–110.0) 0.23
Diastolic BP, mmHg 56.0 (48.0–66.0) 57.0 (48.0–68.0) 56.0 (48.0–64.5) 0.17
Heart rate/min 116.0 (97.0–132.0) 116.0 (97.0–131.0) 115.0 (98.0–134.0) 0.50
Respiratory rate/min 20.0 (18.0–22.0) 20.0 (18.0–23.0) 20.0 (18.0–22.0) 0.25
Body temperature, °C 37.7 (36.8–38.7) 37.8 (36.9–38.8) 37.6 (36.7–38.5) 0.005
Altered mentation 115 (12.8) 71 (15.1) 44 (10.3) 0.03
Laboratory values
White blood cell, /μL 8100 (3000–15,360) 8000 (2870–15,300) 8300 (3140–15,545) 0.56
Hemoglobin, g/dL 10.2 (8.6–11.6) 10.2 (8.5–11.6) 10.1 (8.8–11.8) 0.19
Platelet count, × 1000/μL 143.0 (71.0–232.0) 143.0 (68.0–228.0) 142.5 (77.0–242.5) 0.53
PT, INR 1.29 (1.15–1.47) 1.28 (1.17–1.46) 1.30 (1.15–1.48) 0.96
Albumin, g/dL 2.8 (2.3–3.2) 2.8 (2.4–3.3) 2.7 (2.3–3.2) 0.21
BUN, mg/dL 24.6 (17.4–38.3) 24.3 (17.0–36.0) 25.0 (18.0–41.0) 0.17
Creatinine, mg/dL 1.25 (0.89–1.90) 1.19 (0.87–1.85) 1.32 (0.91–1.95) 0.06
CRP, mg/dL 12.8 (6.1–22.1) 12.3 (6.5–21.7) 13.2 (5.6–23.6) 0.55
Lactic acid, mmol/L 3.6 (2.0–5.5) 3.4 (1.9–5.3) 3.7 (2.2–5.8) 0.03
Severity score
SOFA score 8.0 (6.0–10.0) 7.0 (5.0–10.0) 8.0 (6.0–11.0) 0.002
APACHE II score 20.0 (15.0–26.0) 19.0 (14.0–25.0) 21.0 (15.0–27.0) 0.04
Quick SOFA score 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.50
NEWS 7.0 (5.0–10.0) 7.0 (5.0–10.0) 7.0 (5.0–9.0) 0.99
MEWS 5.0 (4.0–7.0) 5.0 (4.0–7.0) 5.0 (4.0–6.0) 0.75
ICU admission 499 (55.6) 246 (52.5) 253 (59.1) 0.05
28-day mortality 237 (26.4) 120 (25.6) 117 (27.3) 0.55
Values are presented as median (interquartile range) or number (percentage), as appropriate
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, BP blood pressure, BUN blood urea nitrogen, CRP C-reactive protein, ED
emergency department, ICU intensive care unit, INR international normalized ratio, MEWS Modified Early Warning Score, NEWS National Early Warning
Score, PT prothrombin time, SOFA Sequential Organ Failure Assessment
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Table 2 Characteristics of the survivors and non-survivors and the univariable Cox proportional hazards model for 28-day mortality
in the development set
Characteristics Comparison Univariable analysis
Survivors (n = 349) Non-survivors (n = 120) HR 95% CI p value
Age, years 66.0 (60.0–74.0) 69.0 (60.0–75.0) 1.018 1.000–1.036 0.05
Sex
Male 210 (60.2) 82 (68.3) 1.000
Female 139 (39.8) 38 (31.7) 0.739 0.503–1.086 0.12
Hypertension
No 250 (71.6) 76 (63.3) 1.000
Yes 99 (28.4) 44 (36.7) 1.382 0.954–2.004 0.09
Diabetes mellitus
No 260 (74.5) 87 (72.5) 1.000
Yes 89 (25.4) 33 (27.7) 1.144 0.766–1.707 0.51
Cancer type
Lung 40 (11.5) 39 (32.5) 1.000
Hepatobiliary-pancreas 122 (35.0) 29 (24.2) 0.329 0.203–0.533 < 0.001
Gastrointestinal 50 (14.3) 12 (10.0) 0.325 0.170–0.622 0.001
Gynecologic 44 (12.6) 5 (4.2) 0.164 0.065–0.416 < 0.001
Urologic 33 (9.5) 9 (7.5) 0.362 0.175–0.748 0.006
Others 60 (17.2) 26 (21.7) 0.548 0.334–0.901 0.02
Focus of infection
Pneumonia 61 (17.5) 45 (37.5) 1.000
Urinary tract infection 53 (15.2) 12 (10.0) 0.390 0.206–0.738 0.004
Colitis 45 (12.9) 14 (11.7) 0.519 0.285–0.945 0.03
Cholangitis/cholecystitis 106 (30.4) 24 (20.0) 0.387 0.235–0.635 < 0.001
Others/unknown 63 (18.1) 12 (10.0) 0.329 0.174–0.622 0.001
Multiple focus 21 (6.0) 13 (10.8) 0.878 0.474–1.627 0.68
Vital signs at ED admission
Systolic BP, mmHg 90.0 (79.0–110.0) 90.0 (78.0–118.5) 1.004 0.998–1.011 0.20
Diastolic BP, mmHg 57.0 (48.0–66.0) 56.0 (49.0–70.0) 1.005 0.995–1.014 0.33
Heart rate/min 115 (97–131) 117 (96–132) 1.001 0.993–1.008 0.84
Respiratory rate/min 20 (18–22) 22 (20–26) 1.084 1.057–1.113 < 0.001
Body temperature, °C 38.1 (37.1–39.0) 37.3 (36.6–37.9) 0.638 0.546–0.745 < 0.001
Altered mentation 36 (50.7) 35 (49.3) 2.988 2.014–4.431 < 0.001
Laboratory values
White blood cell, /μL 7890 (2740–14,300) 9815 (4365–17,570) 1.000 1.000–1.000 0.04
Hemoglobin, g/dL 10.2 (8.5–11.6) 9.8 (8.4–11.5) 0.994 0.915–1.080 0.88
Platelet count, × 1000/μL 144 (70–228) 140 (66–224) 1.000 0.998–1.001 0.69
PT, INR 1.25 (1.14–1.43) 1.39 (1.25–1.61) 1.229 1.075–1.405 0.003
Albumin, g/dL 2.9 (2.5–3.3) 2.5 (2.2–3.0) 0.451 0.334–0.610 < 0.001
BUN, mg/dL 23 (16–33) 30 (19–44) 1.012 1.005–1.018 0.001
Creatinine, mg/dL 1.16 (0.87–1.80) 1.29 (0.84–2.19) 1.104 0.987–1.233 0.08
CRP, mg/dL 12.0 (5.8–20.6) 14.0 (7.6–25.4) 1.011 0.997–1.026 0.13
Lactic acid, mmol/L 3.1 (1.8–4.9) 4.6 (2.5–8.3) 1.177 1.127–1.228 < 0.001
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ICU care usually exceeds supply, and consequently, the
triage and allocation decisions for ICU care for critically
ill patients are important. Although objective decision-
making guidelines would facilitate the fair use of medical
resources, these guidelines are imprecise and are not suf-
ficiently validated for advanced cancer patients [32–34].
Recently, a new strategy for critically ill cancer patients
has been introduced considering these limitations that
consist of unlimited ICU management with a full-code
status for a limited period [35, 36]. However, this is diffi-
cult to achieve in several hospitals with a chronic short-
age of ICU resources. We believe that the VitaL CLASS
score could help physicians identify those who are more
likely to benefit from invasive ICU management from
those with minimal anticipated benefit, to make better
allocations of medical resources, and to discuss do-not-
attempt-resuscitation or POLST orders in the ED before
admission.
Cancer type is an important prognostic factor for can-
cer patients, and the mortality rate varies by cancer type
in cancer patients with severe sepsis/septic shock [37].
Lung cancer was the second most common cancer type
in our cohort (16.8%), following hepatobiliary-pancreas
cancer (31.9%). In our study, lung cancer patients with
septic shock had the highest 28-day mortality (48.1%)
from septic shock, whereas the mortality rate of gyneco-
logic cancer patients was the lowest (10.2%). These mor-
tality rate differences are consistent with those reported
in previous studies [37]. In our study, lung cancer was
associated with 2.0-fold higher odds when compared
with the other types of cancer. Previous studies demon-
strated that infection focus, such as respiratory infection,
was an important prognostic feature in septic shock pa-
tients, but it was not a significant prognostic factor in
our study for stage IV solid cancer patients with septic
shock [38, 39].
The VitaL CLASS score includes three vital signs at
ED admission: respiratory rate, body temperature, and
mentation. Tachypnea, i.e., respiratory rate ≥ 22, and
altered mentation are commonly used as core poor
prognostic factors, consistent with many previous stud-
ies on prognostic scoring systems such as quick SOFA,
National Early Warning Score, and Modified Early
Warning Score [20–22]. Body temperature < 38.0 °C
(100.4 °F) was another poor prognostic factor in our
prognostic model. Generally, fever is a poor prognostic
sign for septic shock patients. However, for cancer pa-
tients with septic shock who have a suppressed immune
Table 2 Characteristics of the survivors and non-survivors and the univariable Cox proportional hazards model for 28-day mortality
in the development set (Continued)
Characteristics Comparison Univariable analysis
Survivors (n = 349) Non-survivors (n = 120) HR 95% CI p value
Severity scorea
SOFA score 7.0 (5.0–9.0) 10.0 (7.0–13.0) 1.246 1.190–1.305 < 0.001
APACHE II score 18.0 (14.0–23.0) 24.0 (18.0–32.0) 1.088 1.069–1.108 < 0.001
Values are presented as median (interquartile range) or number (percentage), as appropriate
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, BP blood pressure, BUN blood urea nitrogen, CI confidence interval, CRP C-reactive protein,
ED emergency department, HR hazard ratio, INR international normalized ratio, PT prothrombin time, SOFA Sequential Organ Failure Assessment
aSeverity scores were not included in the multivariate analysis for the final model
Table 3 Multivariable analysis model for 28-day mortality in the development set
Characteristics Multivariable analysis Bootstrapping method
HR 95% confidence interval p value Relative frequency*
Lung cancer 2.025 1.345–3.050 0.001 0.959
Vital signs at ED admission
Respiratory rate≥ 22/min 2.517 1.713–3.698 < 0.001 0.858
Body temperature < 38.0 °C 2.918 1.903–4.475 < 0.001 0.994
Altered mentation 2.021 1.328–3.074 0.001 0.923
Laboratory values
Albumin < 2.8 g/dL 2.473 1.665–3.672 < 0.001 0.977
Lactic acid, mmol/L < 0.001
4.0–7.9 1.597 1.032–2.473 0.04 0.997
≥ 8.0 3.767 2.343–6.054 < 0.001
HR hazard ratio
*A 50% relative frequency of selection in bootstrap resampling was the criterion for inclusion of predictors in the final multivariate model
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system, fever implies a protective response, namely that
their innate and adaptive immune system is functioning
better than in those without fever, and such a paradoxical
response has been reported in previous studies [40, 41].
The other two laboratory values were lactic acid and
albumin levels. Serum lactate levels of ≥ 8.0 mmol/L and
from 4.0–7.9 mmol/L were assigned 2 and 1 points,
respectively. Lactate level is a reliable biomarker for out-
come prediction and severity assessment in numerous
conditions [42]. Septic shock according to the Third
International Consensus was defined as refractory
hypotension and serum lactate level of > 2 mmol/L [43].
A lactate level of > 4 mmol/L at ED admission is associ-
ated with mortality in patients with sepsis independent
of organ failure, and we used higher cut-offs of 4.0 and
8.0 mmol/L at ED admission [18, 44]. Serum albumin is
a surrogate marker of visceral protein function and nu-
tritional status [45], but its synthesis is also suppressed
by inflammation [46, 47]. Serum albumin level reflects
both the acute and chronic health status of critically ill
patients [45, 48]. The cut-off level of albumin (< 2.8 g/
dL) in our prediction model is consistent with that used
in previous studies, which showed that hypoalbumin-
emia, defined as < 2.7 or < 2.9 g/dL, was an independent
risk factor for mortality in patients with sepsis [48, 49].
The strength of this study was that the VitaL CLASS
score consisted of variables that are usually assessed
within hours of ED presentation and can be calculated
in the time period before admission. However, several
limitations should be considered when interpreting the
findings of the present study. First, we developed and
validated a new prognostic model for stage IV solid
Table 4 The new prognostic scoring system named VitaL CLASS score (vital signs-lung cancer-lactate-albumin in septic shock)
predicting for 28-day mortality
Risk factor Category Bias-corrected
regression coefficient
Points*
Lung cancer No 0 0
Yes 0.617 1
Vital signs at ED admission
Respiratory rate < 22/min 0 0
≥ 22/min 0.891 1
Body temperature ≥ 38.0 °C 0 0
< 38.0 °C 1.016 2
Mentation Alert 0 0
Alteration 0.645 1
Laboratory values
Albumin ≥ 2.8 g/dL 0 0
< 2.8 g/dL 0.864 1
Lactic acid, mmol/L < 4.0 0 0
4.0–7.9 0.446 1
≥ 8.0 1.228 2
ED emergency department
Total score ranges 0–8
*Risk points were obtained by bias-corrected regression coefficients and reference values in each category. Each risk point was rescaled to designate the point of
lung cancer as 1
Table 5 The C-indices for testing of the VitaL CLASS score and other pre-existing scoring systems
Scoring system Development set Validation set
AIC C-index (95% CI) p value AIC C-index (95% CI) p value
VitaL CLASS score 1287.4 0.808 (0.772–0.845) Reference 1299.1 0.736 (0.694–0.778) Reference
SOFA score 1362.0 0.713 (0.664–0.762) 0.001 1347.2 0.656 (0.603–0.708) 0.01
APACHE II score 1370.3 0.692 (0.643–0.741) < 0.001 1329.1 0.682 (0.633–0.731) 0.08
Quick SOFA score 1419.2 0.614 (0.565–0.663) < 0.001 1380.4 0.552 (0.502–0.601) < 0.001
NEWS 1399.2 0.669 (0.617–0.720) < 0.001 1379.3 0.561 (0.509–0.613) < 0.001
MEWS 1435.5 0.554 (0.501–0.607) < 0.001 1383.6 0.486 (0.433–0.540) < 0.001
AIC Akaike information criterion, APACHE Acute Physiology and Chronic Health Evaluation, CI confidence interval, MEWS Modified Early Warning Score, NEWS
National Early Warning Score, SOFA Sequential Organ Failure Assessment, VitaL CLASS vital signs-lung cancer-lactate-albumin in septic shock
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cancer patients who present with septic shock to the ED
using data from a prospectively collected registry;
however, there was no detailed information on cancer-
related characteristics such as cancer treatment (i.e.,
radiotherapy, chemotherapy, and surgery), response to
therapy, performance status, and time from initial cancer
diagnosis, which are known as major determinant for
the short-term outcome. This was a significant limitation
of our study. However, recent studies demonstrated that
cancer-related characteristics were not associated with
short-term mortality [2, 34, 50]. Additionally, perform-
ance status is still a valid prognostic factor, but its accur-
ate determination at the ED is challenging due to
subjectivity and irreproducibility [51, 52]. Second, the
lack of an external validation sample is another main
limitation of our study, and further studies for validation
of our prognostic model, especially studies involving
other races/ethnicities, are warranted. Third, we divided
the development (January 2016 to December 2017) and
validation sets (January 2018 to June 2019) according to
Fig. 1 Internal validation in the development set (a) and external validation in the validation set (b)
Table 6 Performance of the prognostic model in the development, validation, and combination sets
Total risk points Estimate of
probability
Development set (n = 469) Validation set (n = 428)
Patients, % Observed death within
28 days/patients (%)
Patients, % Observed death within
28 days/patients (%)
0 3.47% 9.6 1/45 (2.2) 9.3 1/40 (2.5)
1 6.33% 15.8 4/74 (5.4) 13.8 5/59 (8.5)
2 11.42% 16.8 5/79 (6.3) 17.8 12/76 (15.8)
3 20.14% 26.7 25/125 (20.0) 22.7 23/97 (23.7)
4 34.10% 15.6 31/73 (42.5) 18.9 30/81 (37.0)
5 53.84% 10.9 34/51 (66.7) 10.5 24/45 (53.3)
6 76.15% 3.4 14/16 (87.5) 5.6 18/24 (75.0)
7 92.99% 0.9 4/4 (100) 1.4 4/6 (66.7)
8 99.28% 0.4 2/2 (100) 0 –
Risk group Estimate of
probability
Patients, % Observed death within
28 days/patients (%)
Patients, % Observed death within
28 days/patients (%)
Low (0–2) 7.07% 42.2 10/198 (5.1) 40.9 18/175 (10.3)
Average (3–5) 36.03% 53.1 90/249 (36.1) 52.1 77/223 (34.5)
High (6–8) 89.47% 4.7 20/22 (90.9) 7.0 22/30 (73.3)
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time, and thus, the characteristics of the cohorts and
treatments could vary according to the study period.
Also, advances in cancer treatment would affect the out-
come, which might be associated with the decrease of
the predictive value in the validation cohort. However,
most variables including outcomes did not show a sig-
nificant difference, and the study period was only 3.5
years. Additionally, the statistically different variables be-
tween development and validation cohorts were not
likely to have a clinically significant impact, e.g., body
temperature (median, 37.8 vs. 37.6 °C, p = 0.005) and lac-
tate level (median, 3.4 vs. 3.7 mmol/L, p = 0.03). Fourth,
the lactate level could be affected by many clinical con-
ditions such as liver cirrhosis, advanced heart failure,
and metformin use. Fifth, all physicians treated patients
according to the current Surviving Sepsis guidelines;
however, in-hospital treatment strategies, such as venti-
lator application or continuous renal replacement ther-
apy, and end-of-life decisions that could affect the
outcome, were not standardized between the participat-
ing hospitals. Lastly, this study did not include the pa-
tients who signed a “do not attempt resuscitation” order
before ED arrival or at the time of diagnosis, which may
lead to a selection bias and limit the generalizability.
Conclusions
In summary, we developed and validated a simple and
objective clinical prediction model, the VitaL CLASS
score, for predicting the 28-day mortality in stage IV
cancer patients who present with septic shock at the ED.
The VitaL CLASS score identified 40.9% of the patients
as having a very low likelihood of 28-day mortality (28-
day mortality in 10.3%, 18/175) with appropriate critical
care and 7.0% of the patients as a high-risk group with
minimal anticipated benefit of invasive ICU treatment
(28-day mortality in 73.3%, 22 of 30). We believe this
prognostic model could provide useful information for
patients, their families, and physicians of different spe-
cialties and can be used as part of a clinical decision-
making strategy regarding aggressive life-sustaining
treatments or POLST orders as well as the triage deci-
sion for ICU admission.
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